202 1 interim report shows that Taizhou Haisheng Pharmaceutical is a holding subsidiary of Xianju Pharmaceutical, and the company holds 6 1.2% equity. It is reported that Haisheng Pharmaceutical's main business is raw material medicine (vitamin D3) and feed additive vitamin (I) (II); Production and sales of vitamin D3. During the reporting period, the operating income was 53.738 million yuan, down 2.965438+06% year-on-year, and the net profit was 3.8494 million yuan, down 80.62% year-on-year. For this transfer, Xianyu Pharmaceutical said that after the effective completion of this equity transfer, the company no longer holds the equity of Haisheng Pharmaceutical, and Haisheng Pharmaceutical is no longer included in the scope of the company's consolidated statements. It is conducive to the company to further focus on the steroid hormone industry chain and optimize its business structure, which is in line with the company's long-term development strategy. The reporter noted that as early as 2020, the net profit of Haisheng Pharmaceutical had already shown a downward trend. The data shows that Haisheng Pharmaceutical achieved a year-on-year decrease in operating income of 65,438+09.50% and a year-on-year decrease in net profit of 34.76%, mainly due to the decline in vitamin prices. At the same time as the listing and transfer of the subsidiary, Xianju Pharmaceutical also plans to invest in the construction of a production line with an annual output of 20 million injections and 200 million capsules as a platform production base for clinical research and commercial production. It is also planned to invest 6543.8 yuan+200 million yuan to build two production lines: long-acting injection production line and antibacterial inhalation preparation production line during perioperative period. The establishment of the production line is conducive to the development of the company's products in the direction of innovative products with good curative effect, low competition and high barriers, enriching the company's preparation product line and promoting the company's industrial competitiveness and sustainable development ability.